Stocks to Watch
Stocks to Watch is Investing Daily’s number one daily offering for investors looking to gain the maximum edge for their portfolio. Full of unique, fresh market insights, Stocks to Watch delivers actionable guidance on the most profitable investment opportunities from today’s headlines.
Check out the Stocks to Watch archive below for in-depth tips and strategies on investing profitably in today’s market. You will uncover how legislation is affecting the economy, where the highest yields are hiding, where strong fundamentals are being overlooked, and much more.
If you’re looking for the latest ideas to invigorate your portfolio, Stocks to Watch is the best place to start.
Certainly, it’s important to keep up with the earnings on the Big Dogs, but it’s always more fun to check in on what’s happening when the Pioneers report.
Canaccord Adams analyst Yuri Lynk released a bullish report on Canada-based infrastructure opportunities, naming Bird Construction Income Fund (TSX: BDT.UN, OTC: BIRDF) among his top picks.
Rice was in the limelight this past week. Costco and Sam’s Club limited the amount of rice customers could buy because of the irrational exuberance of its rice customers. The rice chart below (this is a fairly thin market that’s not too actively traded in the futures) looks like an accelerated rocket ride to the moon. Historically, these kinds of moves always seem to end poorly.
It’s been reported by various sources today that Motorola has begun the Great Reshuffle of its mobile phone division.
Development-stage drug delivery maker pSivida announced today that it intends to reincorporate its operations to its Boston office. The move is intended to expand its visibility—and liquidity—in the US market.
While working VivaGel through its fast-track approval for herpes simplex virus and HIV and teasing out the research on its spermicidal properties in relation to the Durex condom deal, Starpharma discovered that one of the enzymes present in the egg fertilization process is also a key to joint lubrication.
Once more, a major multinational firm has sought out this little Down Under dendrimer company for a development deal.
The trio of Spire Corp, Industrial Nanotech and QinetiQ has posted some very encouraging news in recent weeks that’s starting to reflect in the company’s stock prices.
One of Starpharma's directors has filed that he added another 6 percent to his directly held position in the company in the last month.
In a couple recent announcements in March, Starpharma CEO/Managing Director Jackie Fairley has added 20,000 more shares to her initial position in common stock.